Skip to main content
. 2021 Jan 11;6(1):e144619. doi: 10.1172/jci.insight.144619

Figure 2. CD8+ T cells are required for ZIKV efficacy in mice bearing primary tumors.

Figure 2

(A–D) Absolute numbers of immune cells in the brain at 14 and 21 days after tumor implantation (7 and 14 days after ZIKV treatment). Bars indicate median values. (E and F) Survival analysis of mice bearing GL261 (n = 17–19) (E) or CT2A (n = 14–17) (F) glioma cells, treated with ZIKV or PBS on day 7 and anti-CD8 or isotype control antibody as described in the Methods. Mice without tumor (green lines) (n = 9) were similarly treated. Statistical differences were determined by (A–D) Mann-Whitney U test: *P < 0.05, **P < 0.01, ****P < 0.0001; and log-rank test: ***P < 0.001. All data are pooled from at least 2 to 3 independent experiments. MG, microglia.